Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Sun_Pharmaceutical
|
| gptkbp:acquisitionYear |
2014
|
| gptkbp:ceased_operations |
2014
|
| gptkbp:foundedBy |
gptkb:Bhai_Mohan_Singh
|
| gptkbp:foundedYear |
1961
|
| gptkbp:headquartersLocation |
gptkb:India
gptkb:Gurgaon |
| https://www.w3.org/2000/01/rdf-schema#label |
Ranbaxy Laboratories
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:keyPerson |
gptkb:Malvinder_Mohan_Singh
Daiichi Sankyo (former owner) |
| gptkbp:notableEvent |
US FDA import ban (2008)
paid $500 million fine (2013) settled with US Department of Justice (2013) |
| gptkbp:numberOfEmployees |
~12,000 (2012)
|
| gptkbp:parentCompany |
gptkb:Sun_Pharmaceutical
|
| gptkbp:products |
generic drugs
active pharmaceutical ingredients |
| gptkbp:stockExchange |
gptkb:NSE
BSE |
| gptkbp:successor |
gptkb:Sun_Pharmaceutical
|
| gptkbp:website |
www.ranbaxy.com
|
| gptkbp:bfsParent |
gptkb:Erythropoietin
gptkb:Sun_Pharma gptkb:Daiichi_Sankyo gptkb:Sun_Pharmaceutical_Industries |
| gptkbp:bfsLayer |
6
|